Progress in the Fight Against Multidrug-Resistant Bacteria 2005–2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance

June 22, 2017 at 3:37 pm

Clinical Infectious Diseases July 2017 V.65 N.1 P.141-146

John H. Rex  George H. Talbot  Mark J. Goldberger  Barry I. Eisenstein  Roger M. Echols John F. Tomayko  Michael N. Dudley  Aaron Dane

From a public health perspective, new antibacterial agents should be evaluated and approved for use before widespread resistance to existing agents emerges.

However, for multidrug-resistant pathogens, demonstration of superior efficacy of a new agent over a current standard-of-care agent is routinely feasible only when epidemic spread of these dangerous organisms has already occurred.

One solution to enable proactive drug development is to evaluate new antibiotics with improved in vitro activity against MDR pathogens using recently updated guidelines for active control, noninferiority trials of selected severe infections caused by more susceptible pathogens.

Such trials are feasible because they enroll patients with infections due to pathogens with a “usual drug resistance” phenotype that will be responsive to widely registered standard-of-care comparator antibiotics.

Such anticipatory drug development has constructively reshaped the antibiotic pipeline and offers the best chance of making safe and efficacious antibiotics available to the public ahead of epidemic resistance.



Entry filed under: Antimicrobianos, Bacterias, Epidemiología, Metodos diagnosticos, REPORTS, Resistencia bacteriana, Sepsis.

Practice Patterns and Outcomes Associated With Procalcitonin Use in Critically Ill Patients With Sepsis. Distribution characteristics of Staphylococcus spp. in different phases of periprosthetic joint infection: A review.


June 2017
« May   Jul »

Most Recent Posts

%d bloggers like this: